OXILAN (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity. Its reportedly low viscosity allows it to reach distal vessels. It also has the lowest osmolality of all nonionic monomers in the U.S. Together, these properties facilitate ease of injection, help improve patient comfort and provide visualization and image quality. Recent figures indicate that nearly 2.5 million peripheral procedures are performed annually, the company said.
The contrast media has a molecular structure which includes a hydrophobic region to promote molecular aggregation, thereby reducing the osmolality, Guerbet said. This molecular design also features a terminal hydrophilic group, which results in reduced risk of side effects from binding with biological structures. The hydrophilic group also increases the solubility of the molecule.
Overall, latex-free OXILAN reportedly provides safety and patient tolerability, along with visualization and image quality in peripheral procedures, the company said.
OXILAN is not approved for intrathecal use. Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia and brain edema.
August 17, 2023 
